Table 3 Effect of e-NOS intron 4 VNTR polymorphism and NSAIDs exposure on the risk of UGIH.

From: A multicenter case–control study of the effect of e-nos VNTR polymorphism on upper gastrointestinal hemorrhage in NSAID users

NSAID Exposure

Wildtype genotype

Genetic variation

RERI

(95% CI)

S

(95% CI)

Cases/controls

N/N

OR (95% CI) a;

p value

Cases/controls

N/N

OR (95% CI) a

p value

All NSAIDs

No use

144/465

1.00

51/169

1.14 (0.74, 1.74)

p = 0.5514

−1.35

(−5.73, 3.03)

0.77

(0.31, 1.94)

Use

103/85

6.62 (4.24, 10.36)

p < 0.0001

27/25

5.41 (2.62, 11.15)

p < 0.0001

  

Non-aspirin NASIDs

No use

159/478

1.00

56/171

1.18 (0.78, 1.78)

p = 0.4297

−2.68

(−6.67, 1.31)

0.53

(0.18, 1.55)

Use

88/72

6.52 (4.09, 10.38)

p < 0.0001

22/23

4.02 (1.85, 8.75)

p = 0.0005

  

Aspirin NSAIDs

No use

221/537

1.00

72/190

1.03 (0.70–1.51)

p = 0.8715

0.60

(−8.96, 10.17)

1.14

(0.15, 8.92)

Use

26/13

5.17 (2.11–12.68)

p = 0.0003

6/4

5.80 (1.32–25.46)

p = 0.0197

  
  1. CI, confidence interval; N, number of participants; OR odds ratio; RERI, Relative Excess Risk due to Interaction; S, Synergism Index. a Odds Ratio adjusted for: period of patients’ recruitment, previous history of arthrosis, infection with Helicobacter pylori, gastrointestinal disorders (ulcer and bleeding), exposure to inhibitors of the proton pump, exposure to antiaggregant, exposure to anticoagulants, the number of conducted interviews, and the reliability of the interview. Aspirin subgroup analysis was additionally adjusted for exposure to non-aspirin NSAIDs. RERI = 0 and S = 1 imply no interaction, RERI > 0 and S > 1 imply positive interaction and RERI < 0 and S < 1 imply negative interaction.
Back to article page